CureVac has submitted a preliminary application, a rolling submission, to the European Medicines Agency for use of its COVID-19 vaccine. At this time, the document does not contain all the data needed for approval, but they will be provided to the agency as they become available. The drug is currently in Phase 2b/3 clinical trials in Europe and Latin America under the name HERALD at a dose of 12 mcg for healthy adults.